文献速递神经肿瘤

IDH悖论:IDH野生型与突变型低级别胶质瘤烷化剂化疗的Meta分析

The IDH paradox: Meta-analysis of alkylating chemotherapy in IDH-wild type and -mutant lower grade gliomas.
PubMed 文献 · Neuro Oncol · 2024-01-01

该Meta分析纳入6项随机临床试验共1204例WHO 2-3级胶质瘤患者(430例IDH野生型,774例IDH突变型),评估放疗基础上加用烷化剂化疗的疗效。IDH野生型患者加用烷化剂化疗改善无进展生存期(HR 0.77,95%CI 0.62-0.97,P=0.03)但未改善总生存期(HR 0.87,95%CI 0.64-1.18,P=0.17);IDH突变型患者总生存期(HR 0.52,95%CI 0.42-0.64,P<0.001)和无进展生存期(HR 0.47,95%CI 0.39-0.57,P<0.001)均改善。

要点

  • IDH野生型低级别胶质瘤加用烷化剂化疗改善PFS(HR 0.77)但未改善OS(HR 0.87)。
  • IDH突变型胶质瘤加用烷化剂化疗使死亡风险降低48%、进展风险降低53%。
  • IDH突变型伴或不伴1p19q共缺失的获益幅度相似。

核心结论

  • 烷化剂化疗使IDH突变型胶质瘤患者死亡风险降低48%、进展风险降低53%。
  • IDH野生型弥漫性组织学低级别胶质瘤的最佳管理尚待确定,因少有证据支持烷化剂化疗带来OS获益。

研究设计与样本

  • 对2009年至今发表的WHO 2-3级胶质瘤随机临床试验进行Meta分析,采用随机效应模型及逆方差合并法。
  • 共纳入6项试验、1204例患者(430例IDH野生型,774例IDH突变型),评估烷化剂放化疗对比单纯放疗。

主要发现

  • IDH野生型患者:放疗加烷化剂化疗对比单纯放疗,PFS改善(HR 0.77,95%CI 0.62-0.97,P=0.03),OS无显著改善(HR 0.87,95%CI 0.64-1.18,P=0.17)。
  • IDH突变型患者:放疗加烷化剂化疗对比单纯放疗,OS改善(HR 0.52,95%CI 0.42-0.64,P<0.001),PFS改善(HR 0.47,95%CI 0.39-0.57,P<0.001)。
  • IDH突变型胶质瘤伴或不伴1p19q共缺失的获益幅度相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: IDH-wild type (-wt) status is a prerequisite for the diagnosis of glioblastoma (GBM); however, IDH-wt gliomas with low-grade or anaplastic morphology have historically been excluded from GBM trials and may represent a distinct prognostic entity. While alkylating agent chemotherapy improves overall survival (OS) and progression-free survival (PFS) for IDH-wt GBM and also IDH-mutant gliomas, irrespective of grade, the benefit for IDH-wt diffuse histologic lower-grade gliomas is unclear. METHODS: We performed a meta-analysis of randomized clinical trials for World Health Organization (WHO) grades 2-3 gliomas (2009 to present) to determine the effect of alkylating chemotherapy on IDH-wt and -mutant gliomas using a random-effects model with inverse-variance pooling. RESULTS: We identified 6 trials with 1204 patients (430 IDH-wt, 774 IDH-mutant) that evaluated alkylating chemoradiotherapy versus radiotherapy alone, allowing us to perform an analysis focused on the value of adding alkylating chemotherapy to radiotherapy. For patients with IDH-wt tumors, alkylating chemotherapy added to radiotherapy was associated with improved PFS (HR:0.77 [95% CI: 0.62-0.97], P = .03) but not OS (HR:0.87 [95% CI: 0.64-1.18], P = .17). For patients with IDH-mutant tumors, alkylating chemotherapy added to radiotherapy improved both OS (HR:0.52 [95% CI: 0.42-0.64], P < .001) and PFS (HR = 0.47 [95% CI: 0.39-0.57], P < .001) compared to radiotherapy alone. The magnitude of benefit was similar for IDH-mutant gliomas with or without 1p19q-codeletion. CONCLUSIONS: Alkylating chemotherapy reduces mortality by 48% and progression by 53% for patients with IDH-mutant gliomas. Optimal management of IDH-wt diffuse histologic lower-grade gliomas remains to be determined, as there is little evidence supporting an OS benefit from alkylating chemotherapy.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Kinslow CJ, Roy S, Iwamoto FM, et al. The IDH paradox: Meta-analysis of alkylating chemotherapy in IDH-wild type and -mutant lower grade gliomas. Neuro Oncol. 2024. PMID: 38943513. doi:10.1093/neuonc/noae102

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。